AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11442161
Drug: Medication with
RxNorm normalized name: EUGENOL 850 mg in 1 mL DENTAL LIQUID [Walgreens Natural Eugenol/Toothache Medication with cotton pellets and tweezers]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication with new anticonvulsive drugs (AEDs) and psychosocial counseling (MED group)
Trial: 1531742
Drug: Morphine sulfate
RxNorm normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine sulfate (group M, n = 54, up to 2 mg/kg)
Trial: 1531742
Drug: Morphine sulfate
RxNorm normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine sulfate (group M)
Trial: 29611221
Drug: Minimally rough
RxNorm normalized name: rough marshelder pollen extract
DrugBank: Iva annua pollen (DB10927)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimally rough implants (Turned surface - Tur)
Trial: 29611221
Drug: Moderately rough
RxNorm normalized name: rough marshelder pollen extract
DrugBank: Iva annua pollen (DB10927)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderately rough implants (TiUnite surface - TiU)
Trial: 24752682
Drug: Primaquine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primaquine 0.5 mg/kg per day for 5 days (150 mg total)
Trial: 24752682
Drug: Primaquine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primaquine 0.5 mg/kg per day for 7 days (210 mg total)
Trial: 24752682
Drug: Primaquine 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primaquine 0.25 mg/kg per day for 14 days (210 mg total)
Trial: 17351280
Drug: Ephedrine HCl
RxNorm normalized name: ephedrine HCl
DrugBank: Ephedrine (DB01364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ephedrine HCl (25 mg, 3 times daily) plus caffeine (200 mg, 3 times daily)
Trial: 7608645
Drug: Dietary therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary therapy (Control)
Trial: 2405804
Drug: Cholestyramine resin
RxNorm normalized name: Cholestyramine Resin
DrugBank: Cholestyramine (DB01432)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cholestyramine resin 4 to 12 g twice daily
Trial: 30920620
Drug: Letrozole (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole (2.5 mg/d) for 2 weeks
Trial: 30920620
Drug: Tamoxifen (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen (20 mg/d) for 2 weeks
Trial: 20851843
Drug: IV Δ9‐tetrahydrocannabinol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV Δ9‐tetrahydrocannabinol (THC) 2.5 mg
Trial: 17384438
Drug: Tolvaptan (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolvaptan (30 mg/d)
Trial: 11479396
Drug: L-Dopa alone
RxNorm normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-Dopa alone
Trial: 9692099
Drug: Budesonide 0.2
RxNorm normalized name: budesonide 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 0.2 mg once daily
Trial: 9692099
Drug: Budesonide 0.1
RxNorm normalized name: budesonide 0.125 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 0.1 mg twice daily
Trial: 31959386
Drug: Norepinephrine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine infusion at 0.025 μg kg‐1 min‐1 (Group N1)
Trial: 31959386
Drug: Norepinephrine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine infusion at 0.05 μg kg‐1 min‐1 (Group N2)
Trial: 31959386
Drug: Norepinephrine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine infusion at 0.075 μg kg‐1 min‐1 (Group N3)
Trial: 31959386
Drug: Norepinephrine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine infusion at 0.10 μg kg‐1 min‐1 (Group N4)
Trial: 25204974
Drug: Mesenchymal stromal
RxNorm normalized name: Mesenchymal Stromal Cells
DrugBank: Human Umbilical Cord Mesenchymal Stem Cells (DB15726)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesenchymal stromal cells (MSCs) treatment
Trial: 20739419
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g encapsulated soybean oil/d plus 14.7 g liquid soybean oil/d (control group)
Trial: 20739419
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g encapsulated EPA/d plus 14.7 g liquid soybean oil/d (EPA group)
Trial: 20739419
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g encapsulated soybean oil/d plus 14.7 g liquid SDA-enriched soybean oil/d (SDA group)
Trial: 19202741
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation (200 mg of faropenem)
Trial: 19202741
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation (200 mg of faropenem)
Trial: 30832542
Drug: Telemedicine cochlear
RxNorm normalized name: Cochlearia officinalis leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telemedicine cochlear implant evaluation
Trial: 22582483
Drug: Intravenous intralipid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous intralipid 10% infusion (10 cc/kg)
Trial: 12134253
Drug: Intrapartum nevirapine
RxNorm normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrapartum nevirapine (200 mg to mother and 2 mg/kg to infant)
Trial: 10192340
Drug: Conventional radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional radiotherapy (arm 1): 180 cGy per fraction, total dose 5400 cGy, plus 100 mg/m2 infusional cisplatin.
Trial: 10192340
Drug: Hyperfractionated radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyperfractionated radiotherapy (arm 2): 117 cGy per fraction, total dose 7020 cGy, plus 100 mg/m2 infusional cisplatin.
Trial: 10192340
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (arm 1 and arm 2)
Trial: 8584992
Drug: Warfarin (targeted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (targeted International Normalized Ratio 2.0 to 3.0) for a further eight weeks
Trial: 8584992
Drug: Warfarin for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin for a further eight weeks
Trial: 8584992
Drug: Three months
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three months of warfarin
Trial: 26571827
Drug: Fast neutrons
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast neutrons 6.3 MeV combined with neutron-photon therapy
Trial: 23897424
Drug: 15-μg epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15-μg epinephrine test dose
Trial: 9357205
Drug: Metered Dose
RxNorm normalized name: Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metered Dose Inhaler with Spacer (Group II)
Trial: 8442971
Drug: midazolam 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: midazolam 0.6 mg/kg
Trial: 31278470
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac sodium injection
Trial: 24486592
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of 10% w/w freeze-dried black raspberry gel (BRB), 0.5 g × q.i.d., for 12 weeks
Trial: 24486592
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel (identical formulation devoid of BRB)
Trial: 22395584
Drug: Clindamycin phosphate
RxNorm normalized name: Clindamycin Phosphate
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clindamycin phosphate 1.2% and tretinoin 0.025% combination gel
Trial: 20071811
Drug: Lignocaine with
RxNorm normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lignocaine with adrenaline + 4 mg Dexamethasone (Group C)
Trial: 16871922
Drug: Benzalkonium chloride
RxNorm normalized name: Benzalkonium Chloride
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Benzalkonium chloride (BKC) 0.01% in saline nasal spray
Trial: 11706096
Drug: Bupropion SR
RxNorm normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupropion SR (150 mg daily for 1 week, then 300 mg daily for 5 weeks)
Trial: 9282701
Drug: Group 1
RxNorm normalized name: Chlamydophila psittaci biogroup 1 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1 (prescription and verbal instructions)
Trial: 9282701
Drug: Group 2
RxNorm normalized name: Chlamydophila psittaci biogroup 2 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2 (prescription, syringe, and demonstration)
Trial: 9282701
Drug: Group 3
RxNorm normalized name: Chlamydophila psittaci biogroup 3 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 3 (prescription, syringe with marked line, and demonstration)
Trial: 7942479
Drug: Amiodarone treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone treatment for 3 to 6 months (n = 11)
Trial: 7942479
Drug: Amiodarone treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone treatment for > 1 year (n = 13)
Trial: 23547078
Drug: Rituximab purging
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab purging (P+; 375 mg/m(2) once per week for 4 weeks)
Trial: 23547078
Drug: Maintenance rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Maintenance rituximab (M+; 375 mg/m(2) once every 2 months for four infusions)
Trial: 18171718
Drug: Community based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community based occupational therapy (10 sessions over five weeks)
Trial: 18171718
Drug: Community based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community based occupational therapy
Trial: 17148797
Drug: General anaesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anaesthesia followed by postoperative intravenous patient‐controlled analgesia with morphine
Trial: 17148797
Drug: Combined spinal‐epidural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined spinal‐epidural anaesthesia followed by postoperative epidural infusion of bupivacaine 0.1% with fentanyl 2 microg/mL
Trial: 8785144
Drug: Tramadol 200
RxNorm normalized name: TRAMADOL 200MG (RYZOLT) SA TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 200 mg i.v.
Trial: 8785144
Drug: Tramadol 100
RxNorm normalized name: tramadol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 100 mg i.v.
Trial: 1488688
Drug: Mefloquine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mefloquine (4 tablets, 1000 mg) plus tetracycline (250 mg qid for 7 days)
Trial: 1488688
Drug: MSP (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSP (4 tablets, one tablet contains 250 mg mefloquine, 500 mg sulfadoxine and 25 mg pyrimethamine) plus tetracycline (250 mg qid for 7 days)
Trial: 3698068
Drug: 750-ml spacer
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 750-ml spacer
Trial: 23932140
Drug: Nebulized heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized heparin sulfate 10,000 IU
Trial: 23932140
Drug: Nebulized heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized heparin sulfate 5,000 IU
Trial: 18332450
Drug: IV iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV iron sucrose (200 mg iron) once per week for 4 weeks then once every other week for a further 4 weeks
Trial: 18332450
Drug: Oral ferrous
RxNorm normalized name: ferrous fumarate Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ferrous succinate, 200 mg three times per day for 8 weeks
Trial: 12602671
Drug: Pari Inhalierboy
RxNorm normalized name: Paris quadrifolia extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pari Inhalierboy (2 mg budesonide)
Trial: 12602671
Drug: Pari LC
RxNorm normalized name: Pari LC Pediatric Set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pari LC Jet Plus (2 mg budesonide)
Trial: 12602671
Drug: Maxin MA-2
RxNorm normalized name: Zhi ma oil
DrugBank: Sesame oil (DB11172)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maxin MA-2 (2 mg budesonide)
Trial: 12602671
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg budesonide orally
Trial: 12602671
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg budesonide intravenously
Trial: 10584978
Drug: Fusidic acid
RxNorm normalized name: Fusidic acid
DrugBank: Fusidic acid (DB02703)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fusidic acid 500 mg/day for 28 days (group B)
Trial: 10584978
Drug: Fusidic acid
RxNorm normalized name: Fusidic acid
DrugBank: Fusidic acid (DB02703)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fusidic acid 500 mg/day for 14 days (group A)
Trial: 8947990
Drug: Pharmacist intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist intervention in managing warfarin therapy
Trial: 1835223
Drug: Intramuscular teicoplanin
RxNorm normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular teicoplanin
Trial: 24732048
Drug: Choice to
RxNorm normalized name: TOLNAFTATE 1 g in 100 g TOPICAL CREAM [Quality Choice Tolnaftate Antifungal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Choice to have standard treatment or take part in the trial (choice)
Trial: 17889679
Drug: One-visit treatment
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-visit treatment
Trial: 17889679
Drug: Two-visit treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-visit treatment
Trial: 17889679
Drug: Comparison between
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison between one-visit and two-visit treatments
Trial: 12218286
Drug: Dithranol ointment
RxNorm normalized name: Zithranol
DrugBank: Anthralin (DB11157)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dithranol ointment (2%) once daily for 30 min + vehicle of calcipotriol (50 microg/g) twice daily
Trial: 12218286
Drug: Dithranol ointment
RxNorm normalized name: Zithranol
DrugBank: Anthralin (DB11157)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dithranol ointment (2%) once daily for 30 min + calcipotriol (50 microg/g) twice daily
Trial: 8641492
Drug: Daily hMG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily hMG beginning on cycle day 3 (Group A)
Trial: 8641492
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of CC days 3 through 7 followed by hMG from day 7 onward (Group B)
Trial: 1295525
Drug: Topical dexamethasone
RxNorm normalized name: dexamethasone Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical dexamethasone 0.1% (Maxidex)
Trial: 1295525
Drug: Topical fluorometholone
RxNorm normalized name: Fluorometholone
DrugBank: Fluorometholone (DB00324)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical fluorometholone 0.1% (FML Liquifilm)
Trial: 1295525
Drug: Topical naphazoline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical naphazoline hydrochloride 0.1% (Albalon)
Trial: 1295525
Drug: Combined treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatments (FML and Albalon)
Trial: 6470194
Drug: Thioridazine tablets
RxNorm normalized name: Thioridazine
DrugBank: Thioridazine (DB00679)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thioridazine tablets
Trial: 6470194
Drug: Thioridazine suspension
RxNorm normalized name: Thioridazine
DrugBank: Thioridazine (DB00679)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thioridazine suspension
Trial: 6470194
Drug: Thioridazine tablets
RxNorm normalized name: Thioridazine
DrugBank: Thioridazine (DB00679)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thioridazine tablets and suspension (comparison)
Trial: 22525206
Drug: Metformin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (500 mg once per day)
Trial: 20581787
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 1200 mg/day for 8 weeks
Trial: 22588361
Drug: DHEA (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA (100 mg/day)
Trial: 14530158
Drug: Altered fractionation
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Altered fractionation schemes based on different radiobiological mechanisms; specific dosage and duration not available.
Trial: 10487657
Drug: HRT (transdermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRT (transdermal 17beta‐estradiol, 50 microg/day; plus oral norethisterone acetate, 1 mg/day)
Trial: 10487657
Drug: MFP (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MFP (oral monofluorophosphate, 20 mg/day)
Trial: 8765440
Drug: 7-day continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day continuous etoposide infusion at doses from 30 to 75 mg/m2 per day (schedule A)
Trial: 8765440
Drug: 21-day continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 21-day continuous etoposide infusion at doses from 18 to 40 mg/m2 per day (schedule B)
Trial: 1531552
Drug: Continued treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued treatment by the general practitioner
Trial: 23032981
Drug: Active TENS
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active TENS treatment
Trial: 29429636
Drug: Rivaroxaban 10
RxNorm normalized name: rivaroxaban 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 10 mg/day
Trial: 22336235
Drug: Paclitaxel liposome
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel liposome (135 mg/m²)
Trial: 22336235
Drug: Paclitaxel liposome
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel liposome plus oxaliplatin (135 mg/m² + 125 mg/m²)
Trial: 21030905
Drug: Everolimus with
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus with reduced calcineurin inhibitor exposure
Trial: 17823041
Drug: Outpatient oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient oral hydration and N‐acetylcysteine
Trial: 17823041
Drug: Inpatient intravenous
RxNorm normalized name: Impatiens irvingii whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inpatient intravenous hydration alone (standard therapy)
Trial: 11809337
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg progesterone/g cream
Trial: 11809337
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg progesterone/g cream
Trial: 10416252
Drug: 1% sodium
RxNorm normalized name: Dextrose 5% and 0.11% Sodium Chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% sodium fluorescein solution applied with Pulmicort Topinasal (budesonide) metered pump bottles
Trial: 2842144
Drug: Flumazenil (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flumazenil (1.0 mg)
Trial: 7590022
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of flumazenil (0.25 mg/h)
Trial: 7590022
Drug: Open study
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Open study with flumazenil (1.0 mg)
Trial: 28647339
Drug: Amoxicillin (1500mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin (1500mg/day for 7 days)
Trial: 26521100
Drug: Prasugrel (loading/maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel (loading/maintenance dose: 20/3.75mg)
Trial: 11367898
Drug: Adjuvant systemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant systemic treatment
Trial: 9028057
Drug: Naltrexone (NAL)
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naltrexone (NAL) at doses of 0.5, 1.0 and 1.5 mg/kg every 48 hours
Trial: 1506125
Drug: imidazole 2-hydroxybenzoate
RxNorm normalized name: imidazole-2-hydroxybenzoate
DrugBank: Imidazole salicylate (DB13860)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: imidazole 2-hydroxybenzoate (750 mg, t.i.d., for three days)
Trial: 6360263
Drug: Regimen RSHZ
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen RSHZ (rifampicin, streptomycin, isoniazid, pyrazinamide) daily for 3 months
Trial: 6360263
Drug: Regimen RSHZ/SHZ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen RSHZ/SHZ (rifampicin discontinued after 3 months, remaining drugs given twice weekly for 2 months)
Trial: 6360263
Drug: Basic 3-month
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Basic 3-month regimen followed by unsupervised maintenance therapy with isoniazid for a further 3 months
Trial: 6360263
Drug: Intermittent administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent administration of rifampicin